Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Vaccine. 2012 Apr 27;30 Suppl 1:A101-5. doi: 10.1016/j.vaccine.2011.09.065.
A double-masked, individually randomized Phase 3 clinical trial to assess the efficacy, safety and immunogenicity of the pentavalent rotavirus vaccine (PRV), RotaTeq™, was conducted in rural Matlab, Bangladesh (NCT00362648). A total of 1136 infants were enrolled and randomized to receive either vaccine or placebo in a 1:1 ratio administered with the standard EPI vaccines at a mean age of approximately 8, 12, and 16 weeks. Weight was collected at four time points (study vaccine doses 1, 2, and 3, and a close-out visit in March 2009 at 15-26 months of age), and birth weight was retrospectively collected from information contained on the mother's health card when available. Approximately one year following trial completion a separate study was conducted to collect anthropometry measurements, including weight and height. These measurements were linked with Phase 3 trial data and a post hoc analysis was conducted to assess the effects of rotavirus vaccination on malnutrition among enrolled children who could be located when they were between 27 and 38 months old. Among the 1033 (91%) children located, and measured, for this analysis height-for-age and weight-for-height Z scores were calculated and compared between vaccine and placebo recipients at the anthropometry follow-up 1-year post-trial, and weight-for-age Z scores were calculated at four trial time points in addition to the anthropometry follow-up. The data indicated that there was no effect of rotavirus vaccination on malnutrition in this population at any of the measured time points. PRV, estimated to have about 43% efficacy against severe rotavirus gastroenteritis in this population, may not reduce the overall burden of diarrheal illness sufficiently among all vaccinees to appreciably measure impact on growth compared with non-vaccinees. Regardless of the impact on malnutrition indicators, rotavirus vaccines are an important intervention for reducing morbidity and mortality in children in developing countries.
一项在孟加拉国农村 Matlab 进行的、针对五价轮状病毒疫苗(PRV)Rotateq 的双盲、个体随机的 3 期临床试验,评估其疗效、安全性和免疫原性(NCT00362648)。共有 1136 名婴儿入组并随机分配,以 1:1 的比例接受疫苗或安慰剂,在大约 8、12 和 16 周龄时,与标准 EPI 疫苗联合接种。体重在四个时间点(研究疫苗剂量 1、2 和 3,以及 2009 年 3 月的随访,在 15-26 月龄)进行采集,出生体重从母亲健康卡上的信息中回顾性采集,如果有的话。在试验完成大约一年后,进行了一项单独的研究,以收集人体测量学测量值,包括体重和身高。这些测量值与 3 期试验数据相关联,并进行了事后分析,以评估轮状病毒疫苗接种对入组儿童营养不良的影响,这些儿童在 27-38 月龄时可以找到。在为这项分析找到并测量的 1033 名(91%)儿童中,计算了身高-年龄和体重-身高 Z 评分,并在随访 1 年时比较了疫苗组和安慰剂组的结果,还在除了随访之外的四个试验时间点计算了体重-年龄 Z 评分。数据表明,在任何测量时间点,轮状病毒疫苗接种对该人群的营养不良均无影响。在该人群中,轮状病毒疫苗的估计效力约为 43%,可预防严重轮状病毒胃肠炎,因此,与未接种疫苗者相比,它可能不会显著降低所有接种者腹泻病负担,从而对生长产生影响。无论对营养不良指标的影响如何,轮状病毒疫苗都是发展中国家儿童减少发病率和死亡率的重要干预措施。